WO2017133683A1 - 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e及其制备方法和用途 - Google Patents

一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e及其制备方法和用途 Download PDF

Info

Publication number
WO2017133683A1
WO2017133683A1 PCT/CN2017/072890 CN2017072890W WO2017133683A1 WO 2017133683 A1 WO2017133683 A1 WO 2017133683A1 CN 2017072890 W CN2017072890 W CN 2017072890W WO 2017133683 A1 WO2017133683 A1 WO 2017133683A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
maleate salt
crystal
crystalline
Prior art date
Application number
PCT/CN2017/072890
Other languages
English (en)
French (fr)
Inventor
丁照中
孙飞
胡迎虎
周义龙
王峥
杨玲
Original Assignee
正大天晴药业集团股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2017215800A priority Critical patent/AU2017215800B2/en
Priority to UAA201809085A priority patent/UA123781C2/uk
Application filed by 正大天晴药业集团股份有限公司 filed Critical 正大天晴药业集团股份有限公司
Priority to BR112018015881-0A priority patent/BR112018015881B1/pt
Priority to EA201891770A priority patent/EA038794B1/ru
Priority to NZ745231A priority patent/NZ745231A/en
Priority to ES17747003T priority patent/ES2834303T3/es
Priority to JP2018540750A priority patent/JP6898336B2/ja
Priority to CN201780009746.0A priority patent/CN108602830B/zh
Priority to SG11201806682TA priority patent/SG11201806682TA/en
Priority to MX2018009500A priority patent/MX2018009500A/es
Priority to KR1020187024626A priority patent/KR102393279B1/ko
Priority to CA3013682A priority patent/CA3013682C/en
Priority to US16/075,080 priority patent/US10780091B2/en
Priority to DK17747003.6T priority patent/DK3412671T3/da
Priority to EP17747003.6A priority patent/EP3412671B1/en
Priority to MYPI2018702706A priority patent/MY196762A/en
Publication of WO2017133683A1 publication Critical patent/WO2017133683A1/zh
Priority to ZA2018/05185A priority patent/ZA201805185B/en
Priority to IL260965A priority patent/IL260965B/en
Priority to PH12018501644A priority patent/PH12018501644A1/en
Priority to HK19101224.5A priority patent/HK1259175A1/zh
Priority to US16/991,639 priority patent/US20200368241A1/en

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the invention belongs to the field of medicinal chemistry.
  • the present invention relates to a maleate salt of a TLR7 agonist, a process for the preparation thereof, a pharmaceutical composition comprising the salt, and uses thereof.
  • the present invention also relates to the crystalline form C, the crystalline form D, the crystalline form E of the above salt, a process for preparing the same, a crystalline composition comprising the crystalline form, a pharmaceutical composition comprising the crystalline form or crystalline composition, and a pharmaceutical composition thereof use.
  • Toll-like receptors are expressed by a variety of immune cells. Toll-like receptors recognize highly conserved structural motifs: pathogen-associated microbial patterns (PAMP) expressed by microbial pathogens or damage-associated molecular patterns (DAMP) released by necrotic cells. Activation of the signal cascade by stimulation of Toll-like receptors by the corresponding PAMP or DAMP results in activation of transcription factors such as AP-1, NF- ⁇ B and interferon regulatory factors (impulse response functions). This results in a variety of cellular responses, including the production of interferons, pro-inflammatory cytokines and effector cytokines, thereby eliciting an immune response. To date, 13 Toll-like receptors have been found in mammals.
  • PAMP pathogen-associated microbial patterns
  • DAMP damage-associated molecular patterns
  • Toll-like receptors 1, 2, 4, 5, and 6 are predominantly expressed on the cell surface, while Toll-like receptors 3, 7, 8, and 9 are expressed in endosomes.
  • Different Toll-like receptors can recognize ligands derived from different pathogens.
  • Toll-like receptor 7 (TLR7) is mainly expressed by plasmacytoid dendritic cells (pDC) and induces secretion of interferon alpha (IFN- ⁇ ) by ligand recognition.
  • Toll-like receptor 7 (TLR7) and Toll-like receptor 8 (TLR8) are highly homologous, and thus the TLR7 ligand is in many cases also a TLR8 ligand.
  • TLR8 stimulation primarily induces the production of cytokines such as tumor necrosis factor alpha (TNF-alpha) and chemokines.
  • TNF-alpha tumor necrosis factor alpha
  • Interferon alpha is one of the main drugs for the treatment of chronic hepatitis B or hepatitis C, while TNF- ⁇ is a pro-inflammatory cytokine whose excessive secretion may cause serious side effects.
  • TLR7 agonists have been reported to date, such as Imiquimod (British Journal of Dermatology 2003; 149 (Suppl. 66): 5-8), Resiquimod, Antiviral Research 64 (2004) 79 –83), GS-9620 (Gastroenterology (2013), 144(7), 1508-1517), but there is still a great need for new TLR7 agonists with better selectivity, activity and safety.
  • the invention provides a maleate salt of a compound of formula I:
  • the invention provides a crystalline form of a maleate salt of a compound of formula I, and a corresponding method of preparation and crystalline composition thereof.
  • the crystalline form is Form C, Form D or Form E.
  • XRPD X-ray powder diffraction
  • XRPD X-ray powder diffraction
  • the invention provides a pharmaceutical composition comprising one or more crystalline forms of the invention or crystalline compositions thereof.
  • the pharmaceutical composition may also optionally comprise a pharmaceutically acceptable carrier, excipient and/or vehicle.
  • the present invention provides a method of treating or preventing a Toll-like Receptor 7 (TLR7)-related disease, the method comprising administering to an individual in need thereof an effective amount of a crystalline form of the present invention or a crystal thereof A composition or pharmaceutical composition.
  • TLR7 Toll-like Receptor 7
  • the disease is a viral infection.
  • the invention also provides the use of a crystalline form of the invention, or a crystalline composition or pharmaceutical composition thereof, for the manufacture of a medicament for the treatment or prevention of a Toll-like receptor 7 (TLR7)-related disease.
  • TLR7 Toll-like receptor 7
  • the disease is a viral infection.
  • the invention also provides a crystalline form of the invention, or a crystalline composition or pharmaceutical composition thereof, for use in the treatment or prevention of a Toll-like receptor 7 (TLR7)-related disease.
  • TLR7 Toll-like receptor 7
  • the disease is a viral infection.
  • the viral infection is a hepatitis virus infection, in particular a hepatitis B or hepatitis C virus infection.
  • Figure 1 is an XRPD pattern of Form C of the maleate salt of the compound of Formula I.
  • Figure 2 is an XRPD pattern of Form D of the maleate salt of the compound of Formula I.
  • Figure 3 is an XRPD pattern of Form E of the maleate salt of the compound of Formula I.
  • pharmaceutical composition refers to an active ingredient, optionally in combination with one or more pharmaceutically acceptable chemical ingredients such as, but not limited to, carriers and/or excipients.
  • the active ingredient is, for example, a compound of formula I or a maleate thereof, one or more of the crystalline forms of the invention or one or more of the crystalline compositions of the invention.
  • pharmaceutically acceptable carrier refers to those carriers which have no significant irritation to the organism and which do not impair the biological activity and properties of the active compound.
  • “Pharmaceutically acceptable carrier” means an inert substance which, together with the active ingredient, which facilitates administration of the active ingredient, including, but not limited to, acceptable for human or animal use as permitted by the State Food and Drug Administration (eg Any of the glidants, sweeteners, diluents, preservatives, dyes/colorants, flavor enhancers, surfactants, wetting agents, dispersing agents, disintegrating agents, suspending agents, stabilizers, Isotonicity agent, solvent or emulsifier.
  • Non-limiting examples of such carriers include calcium carbonate, calcium phosphate, various sugars and various types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols, and the like.
  • Other about the carrier For information, reference may be made to Remington: The Science and Practice of Pharmacy, 21 st Ed., Lippincott, Williams & Wilkins (2005), the contents of which are incorporated herein by reference.
  • the term "excipient” generally refers to the vehicle, diluent and/or medium, etc. required to formulate an effective pharmaceutical composition.
  • administering refers to a method by which a compound or composition can be delivered to a desired biological site of action. These methods include, but are not limited to, oral, parenteral (including intravenous, subcutaneous, intraperitoneal, intramuscular, intravascular injection or infusion), topical, rectal administration, and the like.
  • the term "effective amount” refers to a sufficient amount of a drug or agent that is non-toxic but that achieves the desired effect.
  • the "effective amount" of an active substance in the composition can be the amount required to achieve the desired effect when used in combination with another active substance in the composition. The determination of the effective amount will vary from person to person, depending on the age and general condition of the recipient, and also on the particular active substance, and a suitable effective amount in a case can be determined by one skilled in the art based on routine experimentation.
  • active ingredient refers to a chemical entity that is effective to treat or prevent a target disorder, disease or condition.
  • the term may refer to, for example, one or more of the compounds of formula I or their maleates, one or more of the crystalline forms of the invention or the crystalline compositions of the invention.
  • the diffraction pattern obtained from crystalline compounds is often characteristic for a particular crystal form, where the relative intensity of the band (especially at low angles) may be due to crystallization.
  • the dominant orientation effect due to the difference in conditions, particle size, and other measurement conditions varies. Therefore, the relative intensities of the diffraction peaks are not characteristic for the crystal form to be targeted.
  • the position of the peak can be shifted due to changes in temperature during sample analysis, sample movement, or calibration of the instrument, etc., and the measurement error of the 2 ⁇ value is sometimes about ⁇ 0.2°, typically about ⁇ 0.1°. Therefore, this error should be taken into account when determining each crystal structure. If the crystalline form of the invention is described as being substantially as specified in the drawings, the term "substantially” is also intended to encompass such variability in the diffraction peak position.
  • d represents the crystal plane distance
  • ⁇ is Diffraction angle.
  • the peak positions of the XRPD spectrum have similarities as a whole, and the relative intensity error may be large.
  • some of the diffraction lines are missing due to factors such as a decrease in content. At this time, it is not necessary to rely on all the bands observed in the high-purity sample, and even one band may be given.
  • the crystals are characteristic.
  • DSC Differential Scanning Calorimetry
  • DSC differential scanning calorimetry
  • crystalline composition refers to a solid form comprising one or more crystalline forms of the invention (eg, Forms C, D, and/or E).
  • the amount of the crystalline form contained in the crystalline composition may each independently be 50% or more, 80% or more, 90% or more, or 95% or more.
  • the crystalline composition may optionally comprise other crystalline forms or other amorphous forms of a compound of formula I or a salt thereof (such as a maleate) or an impurity other than these.
  • a salt thereof such as a maleate
  • the present invention provides a maleate salt of a compound of formula I:
  • the molar ratio of the compound of formula I to maleic acid in the maleate salt of the compound of formula I is from 1:1 to 3, preferably 1:2.
  • the maleate salt of the compound of formula I of the present invention can be prepared by a conventional maleate salt preparation process.
  • XRPD X-ray diffraction
  • XRPD X-ray diffraction
  • the diffraction peak of Form C of the maleate salt of the compound of Formula I has the following characteristics:
  • the X-ray powder diffraction pattern of Form C of the maleate salt of the compound of Formula I is substantially as shown in FIG.
  • Form C can also be characterized by DSC with an onset temperature of 97.0 ° C ⁇ 5 ° C and a peak temperature of 106.0 ° C ⁇ 5 ° C.
  • the molar ratio of the compound of formula I to the maleic acid in Form C is from 1:1 to 3, preferably 1:2.
  • the present invention also provides a process for the preparation of Form C, which comprises precipitating a maleate salt of a compound of Formula I from a solvent.
  • the method comprises the steps of:
  • the solvent is selected from the group consisting of methanol, ethanol, propanol, isopropanol, n-butanol, isobutanol, tert-butanol, acetone, ethyl acetate and a mixed solvent thereof; preferably ethanol.
  • the amount of the solvent to be added per 1 mol of the compound of the formula I is 0.2 to 8 L, preferably 0.3 to 4 L, more preferably 0.5 to 2 L, and most preferably 1 L.
  • the heating temperature may be from 40 ° C to 90 ° C, preferably from 50 ° C to 80 ° C, more preferably from 70 ° C to 80 ° C.
  • the amount of the maleic acid to be added per 1 mol of the compound of the formula I is 1.0 to 4 mol, preferably 1.6 to 3.0 mol, more preferably 2.0 to 2.4 mol, most preferably 2.2 mol.
  • the invention further relates to a crystalline composition comprising the crystalline form C.
  • Form C comprises 50% or more, preferably 80% or more, more preferably 90% or more, and most preferably 95% or more by weight of the crystalline composition.
  • the crystalline composition in addition to Form C, may comprise other crystalline or amorphous forms of the compound of Formula I or a salt thereof or impurities other than these.
  • XRPD X-ray diffraction
  • XRPD X-ray diffraction
  • XRPD X-ray diffraction
  • the diffraction peak of Form D of the maleate salt of the compound of Formula I has the following characteristics:
  • the X-ray powder diffraction pattern of Form D of the maleate salt of the compound of Formula I is substantially as shown in FIG.
  • Form D can also be characterized by DSC with an onset temperature of 98.3 ° C ⁇ 5 ° C and a peak temperature of 110.1 ° C ⁇ 5 ° C.
  • the molar ratio of the compound of formula I to the maleic acid in Form D is from 1:1 to 3, preferably 1:2.
  • the invention also provides a method of preparing Form D, the method comprising the steps of:
  • the amount of the crystal form C of the maleate salt per 1 g of the compound of the formula I is 2 to 30 mL, preferably 8 to 24 mL, more preferably 12 to 20 mL, still more preferably 14 to 16 mL.
  • the constant temperature is 20 to 60 ° C, preferably 30 to 50 ° C, more preferably 35 to 45 ° C, still more preferably 40 ° C.
  • the invention further relates to a crystalline composition comprising the crystalline form D.
  • Form D is crystalline.
  • the composition has a weight of 50% or more, preferably 80% or more, more preferably 90% or more, and most preferably 95% or more.
  • the crystalline composition in addition to Form D, may comprise other crystalline or amorphous forms of the compounds of formula I or salts thereof or impurities other than these.
  • XRPD X-ray diffraction
  • XRPD X-ray diffraction
  • the diffraction peak of Form E of the maleate salt of the compound of Formula I has the following characteristics:
  • the X-ray powder diffraction pattern of Form E of the maleate salt of the compound of Formula I is substantially as shown in FIG.
  • Form E of the present invention can also be characterized by DSC with an onset temperature of 85.7 ° C ⁇ 5 ° C and a peak temperature of 97.5 ° C ⁇ 5 ° C.
  • the molar ratio of the compound of formula I to the maleic acid in Form E is from 1:1 to 3, preferably 1:2.
  • the invention also provides a method of preparing Form E, the method comprising the steps of:
  • the crystal C of the maleate salt per 1 g of the compound of the formula I corresponds to the amount of isopropanol added in an amount of 2 to 30 mL, preferably 8 to 24 mL, more preferably 12 to 20 mL, further preferably 14 to 16 mL. .
  • the constant temperature is 20 to 60 ° C, preferably 30 to 50 ° C, more preferably 35 to 45 ° C, still more preferably 40 ° C.
  • the invention further relates to a crystalline composition comprising the crystalline form E.
  • Form E is greater than 50% by weight of the crystalline composition, preferably 80% or more, more preferably 90% or more, and most preferably 95% or more.
  • the crystalline composition, in addition to Form E, may comprise other crystalline or amorphous forms of the compound of Formula I or a salt thereof or impurities other than these.
  • the present invention provides a pharmaceutical composition comprising an effective amount of a maleate salt of a compound of formula I; Form C or a crystalline composition comprising said Form C; Form D or comprising said Form D Crystalline composition; or Form E or a crystalline composition comprising the Form E, or any combination thereof.
  • the pharmaceutical compositions may or may not contain pharmaceutically acceptable carriers, excipients, and/or vehicles.
  • the pharmaceutical composition of the present invention can be prepared by combining the compound of the present invention or a salt thereof with a suitable pharmaceutically acceptable carrier, for example, it can be formulated into a solid, semi-solid, liquid or gaseous preparation such as a tablet, a pill, or a capsule.
  • a suitable pharmaceutically acceptable carrier for example, it can be formulated into a solid, semi-solid, liquid or gaseous preparation such as a tablet, a pill, or a capsule.
  • the pharmaceutical composition of the present invention can be produced by a method well known in the art, such as a conventional mixing method, a dissolution method, a granulation method, a drag coating method, a grinding method, an emulsification method, a freeze drying method, and the like.
  • Typical routes of administration of a compound of the invention or a pharmaceutical composition thereof include, but are not limited to, oral, rectal, transmucosal, enteral administration, or topical, transdermal, inhalation, parenteral, sublingual, intravaginal, intranasal, Intraocular, intraperitoneal, intramuscular, subcutaneous, intravenous administration.
  • the pharmaceutical composition is in oral form.
  • the pharmaceutical compositions may be formulated by admixing the active compound withpharmaceutically acceptable carriers, excipients and/or vehicles which are well known in the art. These carriers, excipients and vehicles enable the compounds of the present invention to be formulated into tablets, pills, troches, dragees, capsules, liquids, gels, slurries, suspensions, etc. for oral administration to patients. Dosing.
  • Solid oral compositions can be prepared by conventional methods of mixing, filling or tabletting. For example, it can be obtained by mixing the active compound with a solid excipient, optionally milling the resulting mixture, adding other suitable adjuvants if necessary, and then processing the mixture into granules. The core of a tablet or dragee.
  • Suitable excipients include, but are not limited to, fillers such as sugars including lactose, sucrose, mannitol Or sorbitol; cellulose preparations such as microcrystalline cellulose, corn starch, wheat starch, rice starch and potato starch; and other substances such as silica gel, gelatin, tragacanth, methylcellulose, hydroxypropyl methylcellulose , hydroxymethylcellulose sodium and / or polyvinylpyrrolidone; disintegrating agents, such as sodium carboxymethyl starch, croscarmellose sodium, cross-linked polyvinylpyrrolidone, agar or alginic acid, may also use salts, such as Sodium alginate.
  • the core of the dragee may optionally be coated according to methods well known in the ordinary pharmaceutical practice, especially using enteric coatings.
  • the crystal form C, the crystal form D and the crystal form E of the maleate salt of the compound of the formula I of the invention have the advantages of high purity, high crystallinity, good stability, and the like, and are suitable for preparation for preventing or treating Toll-like samples.
  • Drug for body 7 (TLR7) related diseases are included in the crystal form C, the crystal form D and the crystal form E of the maleate salt of the compound of the formula I of the invention.
  • a pharmaceutical composition comprising an effective amount of a maleate salt of a compound of the formula I as described in the paragraph [1] or [2].
  • the disease is a viral infection, in particular a hepatitis virus infection, such as a hepatitis B or hepatitis C virus infection.
  • the solvent in the step 1) is selected from the group consisting of methanol, ethanol, propanol, isopropanol, n-butanol, isobutanol, tert-butanol, Acetone, ethyl acetate or a mixed solvent thereof.
  • the heating temperature may be selected from 40 ° C to 90 ° C, preferably 50 ° C to 80 ° C, and more. It is preferably 70 ° C to 80 ° C.
  • a pharmaceutical composition comprising an effective amount of the crystalline form C as described in any of paragraphs [6] to [10] or the crystalline composition according to the paragraph [17].
  • the disease is a viral infection, in particular a hepatitis virus infection, such as a hepatitis B or hepatitis C virus infection.
  • the crystal form D according to any one of paragraphs [21] to [24], characterized in that, when characterized by DSC, the starting temperature of the crystal form D is 98.3 ° C ⁇ 5 ° C, the peak value The temperature was 110.1 ° C ⁇ 5 ° C.
  • the constant temperature is 20 to 60 ° C, preferably 30 to 50 ° C, more preferably 35 ⁇ 45 ° C, more preferably 40 ° C.
  • a pharmaceutical composition comprising an effective amount of the crystalline form D as described in any of paragraphs [21] to [25] or the crystalline composition according to the paragraph [29].
  • the disease is a viral infection, in particular a hepatitis virus infection, such as a hepatitis B or hepatitis C virus infection.
  • Form E according to any one of the paragraphs [33]-[35], wherein the Form E has an X-ray powder diffraction pattern substantially as shown in FIG.
  • the amount of the isopropanol added per 1 g of the maleic acid salt of the compound of the formula I is 2 to 2 30 mL, preferably 8 to 24 mL, more preferably 12 to 20 mL, most preferably 14 to 16 mL.
  • the constant temperature is 20 to 60 ° C, preferably 30 to 50 ° C, more preferably 35 to 45 ° C, More preferably, it is 40 °C.
  • a pharmaceutical composition comprising an effective amount of the crystalline form E as described in any of paragraphs [33] to [37] or the crystalline composition according to paragraph [41].
  • the disease is a viral infection, in particular a hepatitis virus infection, such as a hepatitis B or hepatitis C virus infection.
  • SEM-Cl for 2-(trimethylsilyl)ethoxymethyl chloride
  • SEM for 2-(trimethylsilyl)ethoxymethyl
  • DIPEA for diisopropylethylamine
  • TFA stands for trifluoroacetic acid
  • DMF stands for N,N-dimethylformamide
  • n-BuOH stands for n-butanol
  • NH 3 ⁇ H 2 O stands for ammonia water
  • Na stands for sodium metal
  • XRPD stands for X-ray powder diffraction
  • DSC stands for difference Thermal analysis.
  • the compound of formula II (2,4-dichloro-5H-pyrrolo[3,2-d]pyrimidine) (4.00 kg, 21.28 mol) was dissolved in DMF (20.00 L) and batched at room temperature (25 ° C) DIPEA (2.58 kg, 20.00 mol) was added followed by stirring for 30 min.
  • the reaction liquid was cooled to 0 ° C with an ice bath, and then SEM-Cl (4.00 kg, 24.00 mol) was slowly added dropwise at a dropping rate of 1-2 drops/sec over 5 hours. After completion of the dropwise addition, the reaction solution was stirred at 0 ° C for 4 hours. The reaction was monitored by HPLC.
  • the compound of formula V (1.10 kg, 3.27 mol) was dissolved in TFA (5.50 L) and the reaction was stirred at 25 ° C for 16 h.
  • the reaction was monitored by HPLC, the TFA was evaporated under reduced pressure, and the residue was dissolved in methanol (1.2 L) and ice water (1.2 L), and the mixture was adjusted to pH 12 with concentrated aqueous ammonia, then stirred for 2 hours. There are constant precipitations. After filtration, the filter cake was obtained as a white solid, which was purified from 15% aqueous ammonia (1.times.times.times.3) and ethyl acetate (4L) to give the compound of formula VI (550.00g, 2.67mol, 81.7%) as a white solid. .
  • the compound of the formula VIII (440.0 g, 1.11 mol) and dichloromethane (7.0 L) were placed in a 20 L reactor and stirred to cool the system to below -15 °C. After triethylsilane (880 mL, 5.55 mol) was added dropwise to the system, trifluoroacetic acid (880 mL) was further added dropwise, and the temperature was kept below -10 °C during the dropwise addition. After the completion of the dropwise addition, the reaction was carried out at 0 ° C for 2 hr, and the liquid phase was monitored until the starting point disappeared.
  • the reaction mixture was concentrated to dryness, and ethyl acetate (2.2 L) was added, and the mixture was cooled to below 0 °C.
  • the obtained cake was beaten with 2.2 L of water, filtered, and dried under reduced pressure to give 550 g of trifluoroacetic acid salt of the compound of formula I as a white solid.
  • the compound of formula I (3.80 g, 10 mmol) was added to 10 mL of ethanol and dissolved by heating. To the solution was added maleic acid (2.55 g, 22 mmol). The solution was then allowed to naturally cool to room temperature and allowed to stand for 1-2 hours. The precipitate was filtered, and the solid was dried under reduced pressure using an oil pump to give the compound of the formula I, the salt of the compound of the formula I. In the obtained maleate salt, the molar ratio of the compound of the formula I to maleic acid was 1:2.
  • maleate salt form C 50 mg was added 0.8 mL of acetone to form a suspension.
  • the suspension sample was shaken on a thermostat (40 ° C) for 2 days (protected from light).
  • the residual solid was centrifuged and dried overnight in a vacuum oven at 40 ° C to give the compound D of the compound of formula I in solid form.
  • the molar ratio of the compound of the formula I to maleic acid was 1:2.
  • maleate salt form C 50 mg was added 0.8 mL of isopropanol to form a suspension.
  • the suspension sample was shaken on a thermostat (40 ° C) for 2 days (protected from light).
  • the residual solid was centrifuged and dried overnight in a vacuum oven at 40 ° C to give the compound of formula I, maleate salt, E in solid form.
  • the molar ratio of the compound of the formula I to maleic acid was 1:2.
  • Forms C, D and E prepared in Examples 1-3 were placed in open clean containers, respectively, and placed at 60 ° C, and samples were taken on days 10, 20 and 30, respectively. The test results were compared with the initial test results on day 0.
  • the crystal forms C, D and E prepared in Examples 1-3 were respectively placed in a constant temperature and humidity container for accelerated test under the conditions of 40 ° C / 75% humidity (open), and samples were taken on the 30th, 60th and 90th days. Detection. Test results with day 0 The initial test results are compared.
  • Forms C, D, and E prepared in Examples 1-3 were each placed in a light environment of 5000 Lx ⁇ 500 Lx, and samples were taken on Days 5, 10, and 30. The test results were compared with the initial test results on day 0.
  • GS-9620 and R848 used are as follows, wherein GS-9620 can be prepared by the method disclosed in US20100143301; R848 is purchased from Baiqi Bio (Cat. No. IMG-2208, specification 0.5 mg).
  • the culture plate containing the cells and the compound was cultured in a CO 2 incubator for 24 hours under the conditions of 37 ° C, 5% CO 2 concentration.
  • the compound of formula I of the present invention exhibits higher in vitro receptor binding activity to Toll-like receptor 7 than the control (Toll-like receptor 7 agonist GS-9620), as well as the control substance ( Toll-like receptor 7 agonist GS-9620) has lower in vitro receptor binding activity to Toll-like receptor 8.
  • the compounds of the invention have significant selectivity differences for different receptors and are superior to the prior art.
  • the purpose of this example was to detect the expression level of cytokines after stimulating human peripheral blood mononuclear cells (PBMC) for 24 hours using the compound of formula I.
  • the cell supernatant was not diluted at the time of detection, and the level of IFN- ⁇ was directly detected.
  • the compound of formula I was first formulated into a 20 mmol concentration DMSO stock solution, and a 10-fold serial dilution of the cell culture medium was used to dilute a total of 11 points.
  • the compound with 9 dilution points (the highest concentration of compound was 200 ⁇ mol/L) was added to a 96-well plate at 50 ⁇ L per well, and then fresh human peripheral blood mononuclear cells were seeded, and each well was inoculated with 150 ⁇ L of system containing 450,000 cells. .
  • the cell culture plates were incubated for 24 hours at 37 ° C in a 5% CO 2 incubator.
  • the compounds of formula I of the present invention exhibit better IFN-[alpha]-inducing activity of PBMCs in vitro and TNF-[alpha]-inducing activity comparable to the control (GS-9620) compared to the control (GS-9620).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

本发明涉及式I所示化合物的马来酸盐、该盐的制备方法、包含该盐的药物组合物和该盐的用途。本发明还涉及式I所示化合物的马来酸盐的晶型C、晶型D和晶型E；它们的制备方法、包含它们的结晶组合物、药物组合物及用途。

Description

一种TLR7激动剂的马来酸盐、其晶型C、晶型D、晶型E及其制备方法和用途 技术领域
本发明属于药物化学领域。具体而言，本发明涉及一种TLR7激动剂的马来酸盐、其制备方法、包含该盐的药物组合物及其用途。本发明还涉及上述盐的晶型C、晶型D、晶型E、它们的制备方法、包含所述晶型的结晶组合物、包含所述晶型或结晶组合物的药物组合物以及它们的用途。
背景技术
Toll样受体由多种免疫细胞表达。Toll样受体识别高度保守结构基序：由微生物病原体表达的病原体相关的微生物模式(PAMP)或由坏死细胞释放的损伤相关分子模式(DAMP)。通过相应的PAMP或DAMP刺激Toll样受体引发信号级联导致转录因子如AP-1、NF-κB和干扰素调节因子(脉冲响应函数)的激活。这导致多种细胞反应，包括产生干扰素、促炎性细胞因子和效应细胞因子，从而引发免疫应答。迄今为在止哺乳动物中已发现13种Toll样受体。Toll样受体1、2、4、5和6主要表达在细胞表面上，而Toll样受体3、7、8和9表达在内体中。不同的Toll样受体可以识别不同病原体衍生的配体。Toll样受体7(TLR7)主要由浆细胞样树突细胞(pDC)表达，并通过配体识别而诱导干扰素α(IFN-α)的分泌。Toll样受体7(TLR7)和Toll样受体8(TLR8)高度同源，因此TLR7配体在很多情况下也是TLR8配体。TLR8刺激主要诱导产生细胞因子，如肿瘤坏死因子α(TNF-α)和趋化因子。干扰素α是治疗慢性乙型肝炎或丙型肝炎的主要药物之一，而TNF-α则是一种促炎细胞因子，其过多的分泌可能导致严重的副作用。
迄今为止已经报道了几种TLR7激动剂，如咪喹莫特(Imiquimod,British Journal of Dermatology 2003；149(Suppl.66):5–8)、瑞喹莫德(Resiquimod,Antiviral Research64(2004)79–83)、GS-9620(Gastroenterology(2013),144(7),1508-1517)，但具备更好的选择性、活性和安全性的新的TLR7激动剂仍然有很大需求。
中国专利申请201410405136.0(其内容整体援引加入本文)公开了一种这样的小分子，即2-丁氧基-7-(4-(吡咯烷-1-基甲基)苄基)-5H-吡咯并[3,2-d]嘧啶-4-胺及其制备方法，它具有以下结构：
Figure PCTCN2017072890-appb-000001
发明内容
在一方面，本发明提供式I所示化合物的马来酸盐：
Figure PCTCN2017072890-appb-000002
在另一方面，本发明提供式I所示化合物的马来酸盐的晶型及其相应的制备方法和结晶组合物。在一实施方案中，所述晶型为晶型C、晶型D或晶型E。
在一实施方案中，晶型C的特征在于，在X-射线粉末衍射(XRPD)图谱中具有2θ＝7.6°±0.2°、9.9°±0.2°、17.8°±0.2°、22.8°±0.2°、24.2°±0.2°、26.3°±0.2°的衍射峰。
在一实施方案中，晶型D的特征在于，在X-射线粉末衍射(XRPD)图谱中具有2θ＝5.1°±0.2°、9.5°±0.2°、11.2°±0.2°、17.6°±0.2°、20.2°±0.2°、23.0°±0.2°的衍射峰。
在一实施方案中，晶型E的特征在于，在X-射线粉末衍射(XRPD)图谱中具有2θ＝4.9°±0.2°、5.3°±0.2°、9.0°±0.2°、16.5°±0.2°、19.3°±0.2°的衍射峰。
在又一方面，本发明提供一种药物组合物，其包含一种或多种本发明的晶型或其结晶组合物。所述药物组合物还可以任选地包含药学上可接受的载体、赋形剂和/或介质。
在又一方面，本发明还提供一种治疗或预防Toll样受体7(TLR7)相关疾病的方法，所述述方法包括向有此需要的个体给予有效量的本发明的晶型或其结晶组合物或者药物组合物。优选地，所述疾病为病毒感染。
在进一步的方面，本发明还提供本发明的晶型或其结晶组合物或者药物组合物在制备用于治疗或预防Toll样受体7(TLR7)相关疾病的药物中的用途。优选地，所述疾病为病毒感染。
在更进一步的方面，本发明还提供用于治疗或预防Toll样受体7(TLR7)相关疾病的本发明的晶型或其结晶组合物或者药物组合物。优选地，所述疾病为病毒感染。
在本发明的一个实施方案中，所述病毒感染是肝炎病毒感染，特别是乙型或丙型肝炎病毒感染。
附图说明
图1式I所示化合物的马来酸盐的晶型C的XRPD谱图。
图2式I所示化合物的马来酸盐的晶型D的XRPD谱图。
图3式I所示化合物的马来酸盐的晶型E的XRPD谱图。
具体实施方式
一般定义和术语
除非另有说明，本文所用的术语和短语具有下文所列的含义。特定的术语或短语在没有特别定义的情况下不应该认为是不确定的或不清楚的，而应该按照本领域技术人员通常理解的含义进行解释。当本文中出现商品名时，意在指代其对应的商品或其活性成分。
除非另外专门定义，本文中使用的比例(包括百分比)或份数均按重量计。
术语“约”、“大约”当与数值变量并用时，通常指该变量的数值和该变量的所有数值在实验误差内(例如对于平均值95％的置信区间内)或在指定数值的±10％内，或更宽范围内。
表述“包含”或与其同义的类似表述“包括”、“含有”和“具有”等是开放性的，不排除额外的未列举的元素、步骤或成分。表述“由…组成”排除未指明的任何元素、步骤或成分。表述“基本上由…组成”指范围限制在指定的元素、步骤或成分，加上任选存在的不会实质上影响所要求保护的主题的基本和新的特征的元素、步骤或成分。应当理解，表述“包含”涵盖表述“基本上由…组成”和“由…组成”。
术语“任选”或“任选地”是指随后描述的事件或情况可能发生或可能不发生，该描述包括发生所述事件或情况和不发生所述事件或情况。
术语“药物组合物”指活性成分，其任选地与一种或多种药学上可接受的化学成分(例如，但不限于载体和/或赋形剂)组合。所述活性成分例如式I所示化合物或其马来酸盐，本发明的晶型中的一种或多种或者本发明的结晶组合物中的一种或多种。
术语“药学上可接受的载体”是指对有机体无明显刺激作用，而且不会损害该活性化合物的生物活性及性能的那些载体。“药学上可接受的载体”是指与活性成份一同给药的、有利于活性成份给药的惰性物质，包括但不限于国家食品药品监督管理局许可的可接受的用于人或动物(例如家畜)的任何助流剂、增甜剂、稀释剂、防腐剂、染料/着色剂、矫味增强剂、表面活性剂、润湿剂、分散剂、崩解剂、助悬剂、稳定剂、等渗剂、溶剂或乳化剂。所述载体的非限制性实例包括碳酸钙、磷酸钙、各种糖和各类淀粉、纤维素衍生物、明胶、植物油和聚乙二醇等。关于载体的其他 信息，可以参考Remington:The Science and Practice of Pharmacy,21 st Ed.,Lippincott,Williams&Wilkins(2005)，该文献的内容通过引用的方式并入本文。术语“赋形剂”通常是指配制有效的药物组合物所需要的媒介物、稀释剂和/或介质等。
术语“给药”或“给予”等指可以使化合物或组合物能够递送至期望的生物作用位点的方法。这些方法包括但不限于口服、肠胃外(包括静脉内、皮下、腹膜内、肌内、血管内注射或输注)、局部、直肠给药等。
针对药物或药理学活性剂而言，术语“有效量”是指无毒的但能达到预期效果的药物或药剂的足够用量。对于本发明中的口服剂型，组合物中一种活性物质的“有效量”可以是与该组合物中另一种活性物质联用时为了达到预期效果所需要的用量。有效量的确定因人而异，取决于受体的年龄和一般情况，也取决于具体的活性物质，个案中合适的有效量可以由本领域技术人员根据常规试验确定。
术语“活性成分”、“治疗剂”、“活性物质”或“活性剂”是指一种化学实体，它可以有效地治疗或预防目标紊乱、疾病或病症。在本文中，该术语可以指例如式I所示化合物或其马来酸盐，本发明的晶型中的一种或多种或者本发明的结晶组合物中的一种或多种。
在X-射线粉末衍射(XRPD或XRD)光谱中，由结晶化合物得到的衍射谱图对于特定的晶型往往是特征性的，其中谱带(尤其是在低角度)的相对强度可能会因为结晶条件、粒径和其他测定条件的差异而产生的优势取向效果而变化。因此，衍射峰的相对强度对所针对的晶型并非是特征性的，判断是否与已知的晶型相同时，更应该注意的是峰的相对位置而不是它们的相对强度。此外，对任何给定的晶型而言，峰的位置可能存在轻微误差，这在晶体学领域中也是公知的。例如，由于分析样品时温度的变化、样品移动或仪器的标定等，峰的位置可以移动，2θ值的测定误差有时约为±0.2°，典型地约为±0.1°。因此，在确定每种晶型结构时，应该将此误差考虑在内。如果本发明的晶型被描述为基本上如指定附图所示，则术语“基本上”也意图涵盖衍射峰位中的这样的差异性。
在XRPD图谱中通常用2θ角或晶面距d表示峰位置，两者之间具有简单的换算关系：d＝λ/2sinθ，其中d代表晶面距，λ表入射X射线的波长，θ为衍射角。对于同种化合物的同种晶型，其XRPD谱的峰位置在整体上具有相似性，相对强度误差可能较大。还应指出的是，在混合物的鉴定中，由于含量下降等因素会造成部分衍射线的缺失，此时，无需依赖高纯试样中观察到的全部谱带，甚至一条谱带也可能对给定的晶体是特征性的。
差示扫描量热分析(DSC)测定当晶体由于其晶体结构发生变化或晶体熔融而吸收或释放热时的转变温度。对于同种化合物的同种晶型，在连续的分析中，热转变 温度和熔点误差典型的在约5℃之内，通常在约3℃之内。当描述某个化合物具有某一给定的DSC峰或熔点时，指的是该DSC峰或熔点±5℃。DSC提供了一种辨别不同晶型的辅助方法。不同的晶体形态可根据其不同的转变温度特征而加以识别。需要指出的是对于混合物而言，其DSC峰或熔点可能会在更大的范围内变动。此外，由于在物质熔化的过程中伴有分解，因此熔化温度与升温速率相关。
在本文中，差示扫描量热分析(DSC)采用下述方法测定：仪器：TA Q2000差示扫描量热仪；方法：取样品(～1mg)置于DSC铝锅内进行测试，方法为：25℃～300℃，升温速率10℃/min。
术语“结晶组合物”指的是一种固体形式，其包含一种或多种本发明的晶型(例如，晶型C、D和/或E)。在结晶组合物中包含的晶型的量可以各自独立地为50％以上、80％以上、90％以上或95％以上。除了本发明的晶型以外，结晶组合物还可以任选地包含其他晶型或其他无定形形式的式I化合物或其盐(如马来酸盐)或者除了这些物质以外的杂质。本领域技术人员应当理解，结晶组合物中各成分的含量之和应当为100％。
式I所示化合物的马来酸盐
本发明提供式I所示化合物的马来酸盐：
Figure PCTCN2017072890-appb-000003
在一优选实施方案中，在式I所示化合物的马来酸盐中，式I所示化合物与马来酸的摩尔比为1:1～3，优选1:2。本发明的式I所示化合物的马来酸盐可以采用常规的马来酸盐制备工艺来制备。
晶型C
本发明提供式I所示化合物的马来酸盐的晶型C，其在X-射线衍射(XRPD)图谱中具有2θ＝7.6°±0.2°、9.9°±0.2°、17.8°±0.2°、22.8°±0.2°、24.2°±0.2°、26.3°±0.2°的衍射峰。
在一具体实施方案中，晶型C在X-射线衍射(XRPD)图谱中具有2θ＝5.6°±0.2°、7.6°±0.2°、9.9°±0.2°、17.8°±0.2°、19.8°±0.2°、22.8°±0.2°、24.2°±0.2°、25.0°±0.2°、26.3°±0.2°的衍射峰。
在更具体的实施方案中，晶型C在X-射线衍射(XRPD)图谱中具有2θ＝5.6°±0.2°、 6.0°±0.2°、7.6°±0.2°、9.9°±0.2°、12.0°±0.2°、15.3°±0.2°、17.8°±0.2°、18.5°±0.2°、19.8°±0.2°、20.4°±0.2°、22.8°±0.2°、23.1°±0.2°、24.2°±0.2°、24.7°±0.2°、25.0°±0.2°、26.3°±0.2°的衍射峰。
在一特定实施方案中，式I所示化合物的马来酸盐的晶型C的衍射峰具有如下特征：
序号 2θ±0.2(°) 相对强度(％) 序号 2θ±0.2(°) 相对强度(％)
1 5.6 22.0 19 20.7 14.1
2 6.0 18.7 20 21.3 5.8
3 7.6 100.0 21 21.7 5.6
4 9.4 8.0 22 22.4 5.1
5 9.9 87.7 23 22.8 41.9
6 10.2 9.8 24 23.1 17.7
7 11.1 13.8 25 24.2 42.1
8 12.0 16.5 26 24.7 19.7
9 12.9 2.5 27 25.0 26.6
10 15.3 18.7 28 25.4 3.7
11 16.6 5.5 29 25.9 8.7
12 16.9 7.0 30 26.3 35.2
13 17.8 30.0 31 28.0 8.3
14 18.1 9.4 32 28.6 10.9
15 18.5 15.5 33 29.3 4.4
16 19.1 9.9 34 30.4 7.2
17 19.8 25.4 35 33.2 3.5
18 20.4 18.1      
在一实施方案中，式I所示化合物的马来酸盐的晶型C的X-射线粉末衍射图谱基本上如图1所示。
晶型C也可以用DSC进行表征，起始温度为97.0℃±5℃，峰值温度为106.0℃±5℃。
在一实施方案中，晶型C中的式I所示化合物与马来酸的摩尔比为1:1～3，优选1:2。
本发明还提供一种用于制备晶型C的方法，所述方法包括使式I所示化合物的马来酸盐从溶剂中析出。
在一实施方案中，所述方法包括以下步骤：
1)将式I所示化合物溶解于溶剂中，优选通过加热使其溶解；
2)加入马来酸；和
3)冷却析晶、过滤、洗涤并干燥以获得所述晶型C。
在步骤1)中，所述溶剂选自甲醇、乙醇、丙醇、异丙醇、正丁醇、异丁醇、叔丁醇、丙酮、乙酸乙酯及其混合溶剂；优选乙醇。
在步骤1)中，每1mol式I所示化合物对应加入的溶剂量为0.2～8L、优选0.3～4L、更优选0.5～2L，最优选1L。
在步骤1)中，加热温度可以为40℃～90℃、优选50℃～80℃、更优选70℃～80℃。
在步骤2)中，每1mol式I所示化合物对应加入的马来酸的量为1.0～4mol、优选1.6～3.0mol、更优选2.0～2.4mol、最优选2.2mol。
本发明还涉及包含所述晶型C的结晶组合物。在一实施方案中，晶型C占结晶组合物重量的50％以上，优选80％以上，更优选90％以上，最优选95％以上。结晶组合物，除了晶型C以外，还可以包含其他晶型或无定形形式的式I化合物或其盐或者除了这些物质以外的杂质。
晶型D
本发明提供式I所示化合物的马来酸盐的晶型D，其在X-射线衍射(XRPD)图谱中具有2θ＝5.1°±0.2°、9.5°±0.2°、11.2°±0.2°、17.6°±0.2°、20.2°±0.2°、23.0°±0.2°的衍射峰。
在一具体的实施方案中，晶型D在X-射线衍射(XRPD)图谱中具有2θ＝5.1°±0.2°、9.5°±0.2°、11.2°±0.2°、17.6°±0.2°、20.2°±0.2°、20.7°±0.2°、23.0°±0.2°、23.7°±0.2°的衍射峰。
在更具体的实施方案中，晶型D在X-射线衍射(XRPD)图谱中具有2θ＝5.1°±0.2°、5.6°±0.2°、9.5°±0.2°、11.2°±0.2°、16.9°±0.2°、17.6°±0.2°、20.2°±0.2°、20.7°±0.2°、22.6°±0.2°、23.0°±0.2°、23.7°±0.2°、24.5°±0.2°的衍射峰。
在一特定实施方案中，式I所示化合物的马来酸盐的晶型D的衍射峰具有如下特征：
序号 2θ±0.2(°) 相对强度(％) 序号 2θ±0.2(°) 相对强度(％)
1 5.1 100.0 16 19.6 4.4
2 5.6 11.5 17 20.2 35.6
3 7.0 2.7 18 20.7 19.0
4 8.7 2.6 19 21.4 3.5
5 9.5 36.2 20 22.6 12.3
6 10.3 3.1 21 23.0 20.1
7 11.2 23.5 22 23.7 17.7
8 12.0 3.1 23 24.5 14.8
9 14.2 2.5 24 26.4 6.1
10 16.2 4.2 25 27.1 3.1
11 16.9 11.2 26 27.7 3.3
12 17.6 33.6 27 28.4 5.2
13 18.3 4.7 28 28.8 8.7
14 18.8 2.0 29 30.7 3.8
15 19.2 5.3      
在一实施方案中，式I所示化合物的马来酸盐的晶型D的X-射线粉末衍射图谱基本上如图2所示。
晶型D也可以用DSC进行表征，起始温度为98.3℃±5℃，峰值温度为110.1℃±5℃。
在一实施方案中，晶型D中的式I所示化合物与马来酸的摩尔比为1:1～3，优选1:2。
本发明还提供一种制备晶型D的方法，所述方法包括以下步骤：
1)将式I所示化合物的马来酸盐的晶型C置于丙酮溶剂中，形成混悬液；
2)在恒定温度下振摇；
3)离心分离、洗涤并干燥以获得所述晶型D。
在步骤1)中，每1g式I所示化合物的马来酸盐的晶型C对应加入的丙酮的量为2～30mL，优选8～24mL，更优选12～20mL，进一步优选14～16mL。
在步骤2)中，所述恒定温度为20～60℃，优选30～50℃，更优选35～45℃，进一步优选40℃。
本发明还涉及包含所述晶型D的结晶组合物。在一实施方案中，晶型D占结晶 组合物重量的50％以上，优选80％以上，更优选90％以上，最优选95％以上。此外，结晶组合物，除了晶型D外，还可以包含其它晶型或无定形形式的式I化合物或其盐或者除了这些物质以外的杂质。
晶型E
本发明提供式I所示化合物的马来酸盐的晶型E，其在X-射线衍射(XRPD)图谱中具有2θ＝4.9°±0.2°、5.3°±0.2°、9.0°±0.2°、16.5°±0.2°、19.3°±0.2°的衍射峰。
在一具体的实施方案中，晶型E在X-射线衍射(XRPD)图谱中具有2θ＝4.9°±0.2°、5.3°±0.2°、6.7°±0.2°、9.0°±0.2°、10.8°±0.2°、16.5°±0.2°、19.3°±0.2°的衍射峰。
在更具体的实施方案中，晶型E在X-射线衍射(XRPD)图谱中具有2θ＝4.9°±0.2°、5.3°±0.2°、6.7°±0.2°、9.0°±0.2°、10.8°±0.2°、16.2°±0.2°、16.5°±0.2°、19.3°±0.2°、22.0°±0.2°、22.6°±0.2°、25.9°±0.2°的衍射峰。
在一特定实施方案中，式I所示化合物的马来酸盐的晶型E的衍射峰具有如下特征：
序号 2θ±0.2(°) 相对强度(％) 序号 2θ±0.2(°) 相对强度(％)
1 4.9 100.0 9 16.5 15.4
2 5.3 10.4 10 17.7 2.0
3 6.7 6.9 11 19.3 7.2
4 8.2 2.8 12 22.0 4.6
5 8.6 2.7 13 22.6 4.0
6 9.0 7.9 14 24.3 2.3
7 10.8 5.1 15 25.9 3.4
8 16.2 3.9 16 27.1 2.8
在一实施方案中，式I所示化合物的马来酸盐的晶型E的X-射线粉末衍射图谱基本上如图3所示。
本发明的晶型E也可以用DSC进行表征，起始温度为85.7℃±5℃，峰值温度为97.5℃±5℃。
在一实施方案中，晶型E中的式I所示化合物与马来酸的摩尔比为1:1～3，优选1:2。
本发明还提供一种制备晶型E的方法，所述方法包括以下步骤：
1)将式I所示化合物的马来酸盐的晶型C置于异丙醇溶剂中，形成混悬液；
2)在恒定温度下振摇；
3)离心分离、洗涤并干燥以获得所述晶型E。
在步骤1)中，每1g式I所示化合物的马来酸盐的结晶C对应加入的异丙醇的量为2～30mL，优选8～24mL，更优选12～20mL，进一步优选14～16mL。
在步骤2)中，所述恒定温度为20～60℃，优选30～50℃，更优选35～45℃，进一步优选40℃。
本发明还涉及包含所述晶型E的结晶组合物。在一实施方案中，晶型E占结晶组合物重量的50％以上，优选80％以上，更优选90％以上，最优选95％以上。结晶组合物，除了晶型E外，还可以包含其他晶型或无定形形式的式I化合物或其盐或者除了这些物质以外的杂质。
药物组合物和给药
本发明提供一种药物组合物，其包含有效量的式I所示化合物的马来酸盐；晶型C或包含所述晶型C的结晶组合物；晶型D或包含所述晶型D的结晶组合物；或者晶型E或包含所述晶型E的结晶组合物，或其任意组合。此外，该药物组合物还可以包含或不包含药学上可接受的载体、赋形剂和/或介质。
以纯的形式或以适宜的药物组合物形式给药本发明化合物可通过提供类似用途的药剂的任何可接受给药模式来进行。本发明的药物组合物可通过将本发明的化合物或其盐与适宜的药学上可接受的载体组合而制备，例如可配制成固态、半固态、液态或气态制剂，如片剂、丸剂、胶囊剂、粉剂、颗粒剂、膏剂、乳剂、悬浮剂、溶液剂、栓剂、注射剂、吸入剂、凝胶剂、微球及气溶胶等。
本发明的药物组合物可以采用本领域众所周知的方法制造，如常规的混合法、溶解法、制粒法、制糖衣药丸法、磨细法、乳化法、冷冻干燥法等等。
给药本发明的化合物或其药物组合物的典型途径包括但不限于口服、直肠、透黏膜、经肠给药，或者局部、经皮、吸入、肠胃外、舌下、阴道内、鼻内、眼内、腹膜内、肌内、皮下、静脉内给药。
在优选的实施方案中，药物组合物是口服形式。对于口服给药，可以通过将活性化合物与本领域熟知的药物可接受的载体、赋形剂和/或介质混合，来配制该药物组合物。这些载体、赋形剂和介质能使本发明的化合物被配制成片剂、丸剂、锭剂、糖衣剂、胶囊剂、液体、凝胶剂、浆剂、悬浮剂等，用于对患者的口服给药。
可以通过常规的混合、填充或压片方法来制备固体口服组合物。例如，可通过下述方法获得：将所述的活性化合物与固体赋形剂混合，任选地碾磨所得的混合物，如果需要则加入其他合适的辅剂，然后将该混合物加工成颗粒，得到了片剂或糖衣剂的核心。适合的赋形剂包括但不限于：填充剂，如糖，包括乳糖、蔗糖、甘露醇 或山梨糖醇；纤维素制剂例如微晶纤维素、玉米淀粉、小麦淀粉、大米淀粉和马铃薯淀粉；以及其他物质，如硅胶、明胶、黄芪胶、甲基纤维素、羟丙基甲基纤维素、羟甲基纤维素钠和/或聚乙烯吡咯烷酮；崩解剂，如羧甲淀粉钠、交联羧甲基纤维素钠、交联聚乙烯吡咯烷酮、琼脂或藻酸，也可以使用盐，如藻酸钠。可以根据通常药物实践中公知的方法任选地对糖衣剂的核心进行包衣，尤其使用肠溶包衣。
有益效果
本发明的式I所示化合物的马来酸盐的晶型C、晶型D和晶型E具有纯度高、结晶度高、稳定性好等优点，适用于制备用于预防或治疗Toll样受体7(TLR7)相关疾病的药物。
可通过如下段落[1]至段落[44]中所述的内容对本发明的技术方案加以说明：
[1]式I所示化合物的马来酸盐，
Figure PCTCN2017072890-appb-000004
[2]如段落[1]所述的式I所示化合物的马来酸盐，其特征在于，式I所示化合物与马来酸的摩尔比为1:1～3，优选1:2。
[3]一种药物组合物，所述药物组合物包括有效量的如段落[1]或[2]所述的式I所示化合物的马来酸盐。
[4]如段落[1]或[2]所述的式I所示化合物的马来酸盐或者段落[3]所述的药物组合物在制备治疗Toll样受体7相关疾病的药物中的用途。
[5]如段落[4]所述的用途，其特征在于，所述疾病为病毒感染，特别是肝炎病毒感染，如乙型或丙型肝炎病毒感染。
[6]一种式I所示化合物的马来酸盐的晶型C，其特征在于，在X-射线粉末衍射图谱中，具有2θ＝7.6°±0.2°、9.9°±0.2°、17.8°±0.2°、22.8°±0.2°、24.2°±0.2°、26.3°±0.2°的衍射峰。
[7]如段落[6]所述的晶型C，其特征在于，在X-射线粉末衍射图谱中，具有2θ＝5.6°±0.2°、7.6°±0.2°、9.9°±0.2°、17.8°±0.2°、19.8°±0.2°、22.8°±0.2°、24.2°±0.2°、25.0°±0.2°、26.3°±0.2°的衍射峰。
[8]如段落[7]所述的晶型C，其特征在于，在X-射线粉末衍射图谱中，具有2θ＝5.6°±0.2°、6.0°±0.2°、7.6°±0.2°、9.9°±0.2°、12.0°±0.2°、15.3°±0.2°、17.8°±0.2°、 18.5°±0.2°、19.8°±0.2°、20.4°±0.2°、22.8°±0.2°、23.1°±0.2°、24.2°±0.2°、24.7°±0.2°、25.0°±0.2°、26.3°±0.2°的衍射峰。
[9]如段落[6]-[8]中任一项所述的晶型C，其特征在于，所述晶型C具有基本上如图1所示的X-射线粉末衍射图。
[10]如段落[6]-[9]中任一项所述的晶型C，其特征在于，用DSC进行表征时，所述晶型C的起始温度为97.0℃±5℃，峰值温度为106.0℃±5℃。
[11]如段落[6]-[10]中任一段所述的晶型C的制备方法，所述方法包括以下步骤：
1)将式I所示化合物溶解于溶剂中，优选加热使其溶解；
2)加入马来酸；
3)冷却析晶，过滤，洗涤并干燥以获得所述晶型C。
[12]如段落[11]所述的制备方法，其特征在于，步骤1)中所述溶剂选自甲醇、乙醇、丙醇、异丙醇、正丁醇、异丁醇、叔丁醇、丙酮、乙酸乙酯或它们混合溶剂。
[13]如段落[12]所述的制备方法，其特征在于，所述溶剂为乙醇。
[14]如段落[11]-[13]中任一项所述的制备方法，其特征在于，步骤1)中，每1mol式I所示化合物对应加入的溶剂量为0.2～8L、优选0.3～4L、更优选0.5～2L、最优选1L。
[15]如段落[11]-[14]中任一项所述的制备方法，其特征在于，步骤2)中，每1mol式I所示化合物对应加入的马来酸的量为1.0～4mol、优选1.6～3.0mol、更优选2.0～2.4mol、最优选2.2mol。
[16]如段落[11]-[14]中任一项所述的制备方法，其特征在于，步骤1)中，加热温度可选自40℃～90℃、优选50℃～80℃、更优选70℃～80℃。
[17]一种结晶组合物，其特征在于，段落[6]-[10]中任一段所述的晶型C占结晶组合物重量的50％以上，优选80％以上，更优选90％以上，最优选95％以上。
[18]一种药物组合物，包含有效量的如段落[6]-[10]中任一段中所述晶型C或者如段落[17]所述的结晶组合物。
[19]如段落[6]-[10]中任一段所述的晶型C、如段落[17]所述的结晶组合物、或者如段落[18]所述的药物组合物在制备治疗Toll样受体7相关疾病的药物中的用途。
[20]如段落[19]所述的用途，其特征在于，所述疾病为病毒感染，特别是肝炎病毒感染，如乙型或丙型肝炎病毒感染。
[21]一种式I所示化合物的马来酸盐的晶型D，其特征在于，在X-射线粉末衍射图谱中，具有2θ＝5.1°±0.2°、9.5°±0.2°、11.2°±0.2°、17.6°±0.2°、20.2°±0.2°、23.0°±0.2°的衍射峰。
[22]如段落[21]所述的晶型D，其特征在于，在X-射线粉末衍射图谱中，具有2θ＝5.1°±0.2°、9.5°±0.2°、11.2°±0.2°、17.6°±0.2°、20.2°±0.2°、20.7°±0.2°、23.0°±0.2°、23.7°±0.2°的衍射峰。
[23]如段落[22]所述的晶型D，其特征在于，在X-射线粉末衍射图谱中，具有2θ＝5.1°±0.2°、5.6°±0.2°、9.5°±0.2°、11.2°±0.2°、16.9°±0.2°、17.6°±0.2°、20.2°±0.2°、20.7°±0.2°、22.6°±0.2°、23.0°±0.2°、23.7°±0.2°、24.5°±0.2°的衍射峰。
[24]如段落[21]-[23]中任一项所述的晶型D，其特征在于，所述晶型D具有基本上如图2所示的X-射线粉末衍射图。
[25]如段落[21]-[24]中任一项所述的晶型D，其特征在于，用DSC进行表征时，所述晶型D的起始温度为98.3℃±5℃，峰值温度为110.1℃±5℃。
[26]如段落[25]所述的晶型D的制备方法，所述方法包括以下步骤：
1)将式I所示化合物的马来酸盐的晶型C置于丙酮溶剂中，形成混悬液；
2)在恒定温度下振摇；
3)离心分离、洗涤并干燥以获得所述晶型D。
[27]如段落[21]-[26]中任一项所述的制备方法，其特征在于，步骤1)中，每1g式I所示化合物的马来酸盐晶型C对应加入的丙酮的量为2～30mL、优选8～24mL、更优选12～20mL、最优选14～16mL。
[28]如段落[21]-[27]中任一项所述的制备方法，其特征在于，步骤2)中，所述恒定温度为20～60℃、优选30～50℃、更优选35～45℃、进一步优选40℃。
[29]一种结晶组合物，其特征在于，段落[21]-[25]中任一段所述的晶型D占结晶组合物重量的50％以上，优选80％以上，更优选90％以上，最优选95％以上。
[30]一种药物组合物，包含有效量的如段落[21]-[25]中任一段中所述晶型D或者如段落[29]所述的结晶组合物。
[31]如段落[21]-[25]中任一段所述的晶型D、如段落[29]所述的结晶组合物、或者如段落[30]所述的药物组合物在制备治疗Toll样受体7相关疾病的药物中的用途。
[32]如段落[31]所述的用途，其特征在于，所述疾病为病毒感染，特别是肝炎病毒感染，如乙型或丙型肝炎病毒感染。
[33]一种式I所示化合物的马来酸盐的晶型E，其特征在于，在X-射线粉末衍射图谱中，具有2θ＝4.9°±0.2°、5.3°±0.2°、9.0°±0.2°、16.5°±0.2°、19.3°±0.2°的衍射峰。
[34]如段落[33]所述的晶型E，其特征在于，在X-射线粉末衍射图谱中，具有2θ＝4.9°±0.2°、5.3°±0.2°、6.7°±0.2°、9.0°±0.2°、10.8°±0.2°、16.5°±0.2°、19.3°±0.2° 的衍射峰。
[35]如段落[34]所述的晶型E，其特征在于，在X-射线粉末衍射图谱中，具有2θ＝4.9°±0.2°、5.3°±0.2°、6.7°±0.2°、9.0°±0.2°、10.8°±0.2°、16.2°±0.2°、16.5°±0.2°、19.3°±0.2°、22.0°±0.2°、22.6°±0.2°、25.9°±0.2°的衍射峰。
[36]如段落[33]-[35]中任一项所述的晶型E，其特征在于，所述晶型E具有基本上如图3所示的X-射线粉末衍射图。
[37]如段落[33]-[36]中任一项所述的晶型E，其特征在于，用DSC进行表征时，所述晶型E的起始温度为85.7℃±5℃，峰值温度为97.5℃±5℃。
[38]如段落[33]-[37]中任一段所述的晶型E的制备方法，所述方法包括以下步骤：
1)使式I所示化合物的马来酸盐的晶型C置于异丙醇溶剂中，形成混悬液；
2)在恒定温度下振摇；
3)离心分离、洗涤并干燥以获得所述晶型E。
[39]如段落[38]所述的制备方法，其特征在于，步骤1)中，每1g式I所示化合物的马来酸盐的晶型C对应加入的异丙醇的量为2～30mL、优选8～24mL、更优选12～20mL、最优选14～16mL。
[40]如段落[38]或[39]所述的制备方法，其特征在于，步骤2)中，所述恒定温度为20～60℃、优选30～50℃、更优选35～45℃、进一步优选40℃。
[41]一种结晶组合物，其特征在于，段落[33]-[37]中任一段所述的晶型E占结晶组合物重量的50％以上，优选80％以上，更优选90％以上，最优选95％以上。
[42]一种药物组合物，包含有效量的如段落[33]-[37]中任一段中所述晶型E或者如段落[41]所述的结晶组合物。
[43]如段落[33]-[37]中任一段所述的晶型E、如段落[41]所述的结晶组合物、或者如段落[42]所述的药物组合物在制备治疗Toll样受体7相关疾病的药物中的用途。
[44]如段落[43]所述的用途，其特征在于，所述疾病为病毒感染，特别是肝炎病毒感染，如乙型或丙型肝炎病毒感染。
实施例
本文中采用下述缩略词：SEM-Cl代表2-(三甲硅烷基)乙氧甲基氯；SEM代表2-(三甲硅烷基)乙氧甲基；DIPEA代表二异丙基乙基胺；TFA代表三氟乙酸；DMF代表N,N-二甲基甲酰胺；n-BuOH代表正丁醇；NH3·H2O代表氨水；Na代表金属钠；XRPD代表X射线粉末衍射；DSC代表差热分析。
本发明中，X-射线衍射光谱采用下述方法测定：仪器：Bruker D8 ADVANCE X- 射线衍射仪；方法：靶:Cu:K-Alpha；波长λ＝1.54179
Figure PCTCN2017072890-appb-000005
管压Voltage:40kV；管流Current：40mA；扫描范围：4～40°；样品旋转速度：15rpm；扫描速度：10°/分钟。
本发明所使用的所有溶剂是市售的，无需进一步纯化即可使用。制备例中的合成反应一般是在惰性氮气下、无水溶剂中进行的。质子核磁共振数据记录在Bruker Avance III 400(400MHz)分光仪上，化学位移以四甲基硅烷低场处的(ppm)表示。质谱在安捷伦1200系列加6110(&1956A)上进行测定。LC/MS或Shimadzu MS包含一个DAD：SPD-M20A(LC)和Shimadzu Micromass 2020检测器。质谱仪配备有一个正或负模式下操作的电喷雾离子源(ESI)。
制备例1：2-丁氧基-7-(4-(吡咯烷-1-基甲基)苄基)-5H-吡咯并[3,2-d]嘧啶-4-胺马来酸盐的制备
式III：2,4-二氯-5-((2-(三甲基硅基)乙氧基)甲基)-5H-吡咯并[3,2-d]嘧啶
Figure PCTCN2017072890-appb-000006
将式II化合物(2,4-二氯-5H-吡咯并[3,2-d]嘧啶)(4.00kg，21.28mol)溶解于DMF(20.00L)中，在室温(25℃)下分批加入DIPEA(2.58kg，20.00mol)，随后搅拌30min。将反应液用冰浴降温至0℃，然后在5小时内，以1～2滴/秒的滴速，缓慢滴加SEM-Cl(4.00kg，24.00mol)。滴加完成后，将反应液在0℃下搅拌反应4小时。HPLC监测反应完全，将反应液用70L水淬灭稀释后，用乙酸乙酯(15L×3)萃取。将合并的有机相依次用1M的盐酸水溶液(5L×2)和饱和食盐水(7L×2)洗涤，减压蒸馏除去溶剂后得式III化合物(6.40kg，20.11mol，产率94.50％)。
1H NMR(400MHz,DMSO-d6)δ8.24-8.35(m,1H)，6.70-6.85(m,1H)，5.77(s,2H)，3.45-3.57(m,2H)，0.74-0.86(m,2H)，0.00(s,9H)。
式IV：2-氯-5-((2-(三甲基硅基)乙氧基)甲基)-5H-吡咯并[3,2-d]嘧啶-4-胺
Figure PCTCN2017072890-appb-000007
在10L高压釜中，将式III化合物(1.60kg,5.03mol)溶于异丙醇(1.60L)中。在室温(25℃)下一次性加入氨水(4L)，将反应混合物在95℃下搅拌7小时。HPLC监测反应完毕，使反应液自然冷却到室温，经布氏漏斗过滤后得到黑褐色固体。将该 固体依次用乙酸乙酯/正庚烷(1/1，5L×2)打浆，用乙酸乙酯(4L)打浆，得到棕色固体形式的式IV化合物(1.25kg,4.18mol，产率83.1％)。
1H NMR(400MHz,DMSO-d6)δ7.61-7.77(m,1H)，6.97-7.19(m,2H)，6.28-6.38(m,1H)，5.54-5.67(m,2H)，3.43-3.53(m,2H)，0.76-0.91(m,2H)，0.07(s,9H)。
式V：2-丁氧基-5-((2-(三甲基硅)基乙氧基)甲基)-5H-吡咯并[3,2-d]嘧啶-4-胺
Figure PCTCN2017072890-appb-000008
在氮气保护下，将金属钠(525.05g，22.84mol)缓慢分批加入到n-BuOH(17.0L)中。加入完毕后，使体系升温至60℃，并在该温度下持续搅拌，直至金属钠全部溶解。随后，使体系冷却至25℃，将式IV化合物(1.95kg，6.53mol)分批加入，搅拌混合均匀后，将反应物在90℃下持续搅拌8小时。HPLC监测反应完全，使反应混合物自然降温至25℃后，缓慢倒入30L饱和氯化铵水溶液中。随后用乙酸乙酯(15L×3)萃取，将合并的有机相用饱和食盐水(20L×2)洗涤，经无水Na2SO4干燥、过滤。减压蒸馏除去溶剂后，将残余物在正庚烷(4L)中打浆，过滤分离得到固体，将其在乙酸乙酯(5L)中打浆，得到黄白色固体形式的式V化合物(1.53kg，4.55mol，69.7％)。
1H NMR(400MHz,DMSO-d6)δ7.49-7.54(m,1H)，6.54-6.62(m,2H)，6.15-6.20(m,1H)，5.54(s,2H)，4.10-4.22(m,2H)，3.42-3.55(m,2H)，1.58-1.73(m,2H)，1.35-1.47(m,2H)，0.90-0.96(m,3H)，0.83-0.89(m,2H)，0.05(s,9H)。式VI：2-丁氧基-5H-吡咯并[3,2-d]嘧啶-4-胺
Figure PCTCN2017072890-appb-000009
将式V化合物(1.10kg,3.27mol)溶于TFA(5.50L)，将反应液在25℃下持续搅拌16小时。HPLC监测反应完全，减压蒸馏除去TFA，将剩余物溶解在甲醇(1.2L)和冰水(1.2L)中，均匀搅拌下，用浓氨水调节体系pH至12，然后搅拌2小时，溶液中不断有沉淀析出。过滤后，滤饼为白色固体，将其依次用15％的氨水(1.2L×3)和乙酸乙酯(4L)打浆，得到白色固体形式的式VI化合物(550.00g，2.67mol，81.7％)。
1H NMR(400MHz,甲醇-d4)δ7.37(d,J＝2.89Hz,1H)，6.29(d,J＝3.01Hz,1H)，4.27(t,J＝6.53Hz,2H)，1.75(d,J＝7.91Hz,2H)，1.44-1.61(m,2H)，1.00(t,J＝7.40 Hz,3H)。
式VII：4-((4-氨基-2-丁氧基-5H-吡咯并[3,2-d]嘧啶-7-基)-羟基甲基)苯甲醛
Figure PCTCN2017072890-appb-000010
将对苯二甲醛(790.64mg，5.82mmol)和异丙醇(10mL)投入至三口瓶中，在搅拌下加入2-丁氧基-5H-吡咯并[3,2-d]嘧啶-4-胺(1.00g，4.85mmol)，将体系降温至0℃，之后继续搅拌10min。加入纯化水(10mL)和碳酸钾(804.17mg，5.82mmol)，并在25℃下反应16hr，LCMS监控至原料反应完全。反应完全后，有固体析出。过滤后，将所得固体用20mL纯化水打浆，用30mL(乙酸乙酯/正庚烷＝1/20)打浆，过滤，干燥，得到黄色固体形式的式VII化合物(1.50g，4.41mmol，收率：90.9％)。
1H NMR(400MHz,甲醇-d4)δ9.94(s,1H),7.86(d,J＝8.16Hz,2H),7.72(d,J＝8.16Hz,2H),7.12-7.17(m,1H),6.19(s,1H),4.28(t,J＝6.53Hz,2H),1.68-1.77(m,2H),1.44-1.54(m,2H),0.97(t,J＝7.34Hz,3H)。
式VIII：(4-氨基-2-丁氧基-5H–吡咯并[3,2-d]嘧啶-7-基)(4-(吡咯烷-1-基甲基)苯基)甲醇
Figure PCTCN2017072890-appb-000011
将式VII化合物(450.0g，1.32mol)和异丙醇(4.5L)投入30L反应釜中，搅拌5min，之后加入冰醋酸(119.0g，1.98mol)，搅拌降温至0-10℃。滴加吡咯烷(112.4g，1.58mol)，在滴加中保持温度低于10℃。滴加完成后，分批次加入三乙酰氧基硼氢化钠(420.0g，1.98mol)，并在10-20℃下反应3hr，液相监控至原料完全消失。反应完全后，加入纯化水5L，使溶液温度降至-10℃左右，加入15％氨水12L，加入过程中保持溶液温度低于0℃。搅拌时有固体析出。过滤，将所得滤饼用2L水打浆，用2L×2乙酸乙酯打浆，过滤，在40℃减压烘干12hr，得到黄色固体形式的式VIII化合物(465.0g，1.18mol，收率89.4％，水分0.9％)。
1H NMR(400MHz,甲醇-d4)δ7.46(d,J＝7.91Hz,1H),7.29(d,J＝8.03Hz,1H),7.09(s,1H),6.12(s,1H),4.29(t,J＝6.53Hz,2H),3.60(s,2H),2.52(br.s.,4H), 1.66-1.83(m,6H),1.49(d,J＝7.53Hz,2H),0.98(t,J＝7.40Hz,3H)。
式I：2-丁氧基-7-(4-(吡咯烷-1-基甲基)苄基)-5H-吡咯并[3,2-d]嘧啶-4-胺
Figure PCTCN2017072890-appb-000012
将式VIII化合物(440.0g，1.11mol)和二氯甲烷(7.0L)投入20L反应釜中，搅拌使体系降温至-15℃以下。向体系中滴加三乙基硅烷(880mL，5.55mol)后，继续滴加三氟乙酸(880mL)，在滴加中保持温度低于-10℃。滴加完毕后，在0℃下反应2hr，液相监控至原料点消失。反应完全后，将反应液浓缩至干，加入乙酸乙酯2.2L，搅拌使体系降温至0℃以下。之后加入饱和碳酸钠溶液调节溶液pH＝9-10，在此过程中保持体系温度低于10℃。过滤，将所得滤饼用2.2L水打浆后过滤，减压烘干，得到白色固体形式的式I化合物的三氟乙酸盐550g。
将525g白色固体形式的式I化合物的三氟乙酸盐加入1.6L乙醇中，搅拌使体系降温至0℃左右，之后加入1mol/L氢氧化钠溶液2.2L。过滤，将滤饼用2.5L纯化水打浆，过滤，将滤饼减压烘干得到固体形式的式I化合物380.0g。
1H NMR(400MHz,甲醇-d4)δ7.27(d,J＝8.0Hz,2H),7.22(d,J＝8.0Hz,2H),7.04(s,1H),4.32(t,J＝6.6Hz,2H),3.99(s,2H),3.60(s,2H),2.55-2.52(m,4H),1.85-1.71(m,6H),1.55-1.48(m,2H),1.00(t,J＝7.4Hz,3H)。
实施例1：2-丁氧基-7-(4-(吡咯烷-1-基甲基)苄基)-5H-吡咯并[3,2-d]嘧啶-4-胺马来酸盐晶型C的制备
向10mL乙醇中加入式I化合物(3.80g，10mmol)，并加热溶解，向溶液中加入马来酸(2.55g，22mmol)，继续加热搅拌至澄清。然后使溶液自然冷却到室温，放置1-2小时。将沉淀过滤，将固体用油泵减压干燥，得到固体形式的式I化合物马来酸盐晶型C。所得的马来酸盐中，式I所示化合物与马来酸的摩尔比为1:2。
采用下述方法对XRPD进行测定：仪器：Bruker D8 ADVANCE X-射线衍射仪；方法：靶:Cu:K-Alpha；波长λ＝1.54179
Figure PCTCN2017072890-appb-000013
管压Voltage:40kV；管流Current：40mA；扫描范围：4～40°；样品旋转速度：15rpm；扫描速度：10°/分钟。
结果显示，所获得的化合物晶体具有基本上如图1所示的衍射峰。
实施例2：2-丁氧基-7-(4-(吡咯烷-1-基甲基)苄基)-5H-吡咯并[3,2-d]嘧啶-4-胺马来酸 盐晶型D的制备
将式I化合物马来酸盐晶型C(50mg)中加入0.8mL丙酮形成悬浊液。将悬浊液样品置于恒温均匀仪上(40℃)振摇2天(避光)。将残留的固体物离心分离，并在40℃真空干燥箱中干燥过夜得到固体形式的式I化合物马来酸盐晶型D。所得马来酸盐中，式Ⅰ所示化合物与马来酸的摩尔比为1:2。
采用下述方法对XRPD进行测定：仪器：Bruker D8 ADVANCE X-射线衍射仪；方法：靶:Cu:K-Alpha；波长λ＝1.54179
Figure PCTCN2017072890-appb-000014
管压Voltage:40kV；管流Current：40mA；扫描范围：4～40°；样品旋转速度：15rpm；扫描速度：10°/分钟。
结果显示，所获得的化合物晶体具有基本上如图2所示的衍射峰。
实施例3：2-丁氧基-7-(4-(吡咯烷-1-基甲基)苄基)-5H-吡咯并[3,2-d]嘧啶-4-胺马来酸盐晶型E的制备
将式I化合物马来酸盐晶型C(50mg)中加入0.8mL异丙醇形成悬浊液。将悬浊液样品置于恒温均匀仪上(40℃)振摇2天(避光)。将残留的固体物离心分离，并在40℃真空干燥箱中干燥过夜得到固体形式的式I化合物马来酸盐晶型E。所得马来酸盐中，式Ⅰ所示化合物与马来酸的摩尔比为1:2。
采用下述方法对XRPD进行测定：仪器：Bruker D8 ADVANCE X-射线衍射仪；方法：靶:Cu:K-Alpha；波长λ＝1.54179
Figure PCTCN2017072890-appb-000015
管压Voltage:40kV；管流Current：40mA；扫描范围：4～40°；样品旋转速度：15rpm；扫描速度：10°/分钟。
结果显示，所获得的化合物晶体具有基本上如图3所示的衍射峰。
实施例4：高温稳定性试验
依据《原料药与药物制剂稳定性试验指导原则》(中国药典2010版附录XIXC)，考察实施例1-3中制备的晶型在加速试验高温条件下的稳定性。
将实施例1-3中制备的晶型C、D和E分别置于开口洁净容器中，于60℃下放置，分别于第10、20和30天取样检测。将检测结果与第0天的初始检测结果进行比较。
实施例5：高湿稳定性试验
依据《原料药与药物制剂稳定性试验指导原则》(中国药典2010版附录XIXC)，考察实施例1-3中制备的晶型在加速试验高湿条件下的稳定性。
将实施例1-3中制备的晶型C、D和E分别置于恒温恒湿容器中进行加速试验，条件为40℃/75％湿度(敞口)，于第30、60和90天取样检测。将检测结果与第0天 的初始检测结果进行比较。
实施例6：光照稳定性
依据《原料药与药物制剂稳定性试验指导原则》(中国药典2010版附录XIXC)，考察实施例1-3中制备的晶型在光照条件下的稳定性。
将实施例1-3中制备的晶型C、D和E分别置于5000Lx±500Lx的光照环境下，于第5天、第10天和第30天取样。将检测结果与第0天的初始检测结果进行比较。
药物活性效果实施例
效果实施例1：Toll样受体7和Toll样受体8体外受体结合活性筛选方案
试剂：
HEK-blue hTLR7细胞和HEK-blue hTLR8细胞(来源于InvivoGen公司)
DMEM培养基
热灭活胎牛血清
抗支原体试剂NormocinTM
博来霉素
杀稻瘟菌素
所用的GS-9620和R848的结构如下，其中GS-9620可以参考US20100143301中公开的方法制备；R848购自百奇生物(货号IMG-2208，规格0.5mg)。
Figure PCTCN2017072890-appb-000016
方案：
(1)96孔化合物板的准备：利用液体工作站POD将化合物从10mmol/L浓度起始，用DMSO做3倍梯度稀释，共稀释10个点(从第2列到第11列，每个点2个重复)。在第12列加入1μL 5mg/mL的阳性化合物R848作为阳性对照，在第1列加入1μL DMSO作为阴性对照。每孔中含有的DMSO体积均为1μL。
(2)收集细胞培养瓶中的细胞，将细胞密度稀释成250,000个细胞/mL。
(3)加入200μL(50,000个细胞/孔)细胞悬液至准备好的化合物板中。每孔中DMSO 终浓度为0.5％。
(4)将含有细胞和化合物的培养板放入CO2培养箱中培养24小时，培养条件为37℃，5％CO2浓度。
(5)培养24小时后，从细胞培养板中每孔取出20μL上清液转移到一块96孔透明检测板中。然后往检测板中每孔加入180μL Quanti-Blue试剂，并置于37℃，5％CO2培养箱孵育1小时。
(6)1小时后，用酶标仪OD650读板检测20μL上清液中碱性磷酸酶的含量。
(7)利用Prism软件分析数据，得出各化合物的EC50。
实验结果如表1所示：
表1
化合物名称 TLR7 EC50(nM) TLR8 EC50(nM)
GS-9620 517 7867
式I化合物 160 11632
从上表可见，本发明的式I所示化合物展现出比对照品(Toll样受体7激动剂GS-9620)更高的与Toll样受体7体外受体结合活性，以及比对照品(Toll样受体7激动剂GS-9620)更低的与Toll样受体8体外受体结合活性。本发明的化合物对不同受体具有明显的选择性差异，且效果优于现有技术。
效果实施例2外周血单个核细胞试验方案
本实施例的目的在于检测利用式I所示化合物刺激人外周血单核细胞(PBMC)24h后细胞因子的表达水平。
检测时细胞上清液不稀释，直接检测IFN-α的水平。首先将式I的化合物配制成20mmol浓度的DMSO储存液，用细胞培养基做10倍梯度稀释，总共稀释11个点。取其中9个稀释点的化合物(化合物的最高浓度为200μmol/L)加入96孔板中，每孔50μL，然后接种新鲜的人外周血单核细胞，每孔接种150μL体系，其中含有450,000个细胞。将细胞培养板置于37℃和5％CO2培养箱中培养24小时。培养结束后将培养板以1200rpm的速度离心5分钟，随后收集上清并将其储存于-20℃以待检测。细胞因子的检测利用BD公司的流式液相多重蛋白定量技术(CBA)，在流式细胞仪上完成检测。利用上述检测方法，我们将刺激产生30pg/mL的IFN-α的最低药物浓度，定义为该化合物在该细胞因子刺激实验上的MEC值。实验结果如下表2所示。
表2
化合物名称 IFN-αMEC(nM) TNF-αMEC(nM)
GS-9620 50 500
式I的化合物 5 500
结论：本发明的式I化合物展示出比对照品(GS-9620)更好的体外PBMC的IFN-α诱导活性以及与对照品(GS-9620)相当的TNF-α的诱导活性。

Claims (10)

  1. 式I所示化合物的马来酸盐
    Figure PCTCN2017072890-appb-100001
  2. 式I所示化合物的马来酸盐的晶型C，其特征在于，在X-射线粉末衍射图谱中，所述晶型C具有2θ＝7.6°±0.2°、9.9°±0.2°、17.8°±0.2°、22.8°±0.2°、24.2°±0.2°、26.3°±0.2°的衍射峰，
    Figure PCTCN2017072890-appb-100002
  3. 一种制备权利要求2所述的晶型C的方法，所述方法包括以下步骤：
    1)将式I所示化合物溶解于溶剂中；
    2)加入马来酸；和
    3)冷却析晶，过滤，洗涤并干燥以获得所述晶型C，
    其中所述溶剂选自甲醇、乙醇、丙醇、异丙醇、正丁醇、异丁醇、叔丁醇、丙酮、乙酸乙酯及其混合溶剂；优选乙醇。
  4. 式I所示化合物的马来酸盐的晶型D，其特征在于，在X-射线粉末衍射图谱中，所述晶型D具有2θ＝5.1°±0.2°、9.5°±0.2°、11.2°±0.2°、17.6°±0.2°、20.2°±0.2°、23.0°±0.2°的衍射峰，
    Figure PCTCN2017072890-appb-100003
  5. 一种制备权利要求4所述的晶型D的方法，所述方法包括以下步骤：
    1)将式I所示化合物的马来酸盐的晶型C置于丙酮溶剂中，形成混悬液；
    2)在恒定温度下振摇；和
    3)离心分离、洗涤并干燥以获得所述晶型D。
  6. 式I所示化合物的马来酸盐的晶型E，其特征在于，在X-射线粉末衍射图谱中，所述晶型E具有2θ＝4.9°±0.2°、5.3°±0.2°、9.0°±0.2°、16.5°±0.2°、19.3°±0.2°的衍射峰，
    Figure PCTCN2017072890-appb-100004
  7. 一种制备权利要求6所述的晶型E的方法，所述方法包括以下步骤：
    1)将式I所示化合物的马来酸盐的晶型C置于异丙醇溶剂中，形成混悬液；
    2)在恒定温度下振摇；和
    3)离心分离、洗涤并干燥以获得所述晶型E。
  8. 一种结晶组合物，其特征在于，
    权利要求2所述的晶型C占所述结晶组合物重量的50％以上，优选80％以上，更优选90％以上，最优选95％以上；或者
    权利要求4所述的晶型D占所述结晶组合物重量的50％以上，优选80％以上，更优选90％以上，最优选95％以上；或者
    权利要求6所述的晶型E占所述结晶组合物重量的50％以上，优选80％以上，更优选90％以上，最优选95％以上。
  9. 一种药物组合物，其特征在于，所述药物组合物包含有效量的权利要求1所述的式I所示化合物的马来酸盐、权利要求2所述的晶型C、权利要求4所述的晶型D、权利要求6所述的晶型E、权利要求8所述的结晶组合物或者它们的任意组合。
  10. 权利要求1所述的式I所示化合物的马来酸盐、权利要求2所述的晶型C、权利要求4所述的晶型D、权利要求6所述的晶型E、权利要求8所述的结晶组合物或权利要求9所述的药物组合物在制备用于治疗Toll样受体7相关疾病的药物中的用途。
PCT/CN2017/072890 2016-02-05 2017-02-04 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e及其制备方法和用途 WO2017133683A1 (zh)

Priority Applications (21)

Application Number Priority Date Filing Date Title
MYPI2018702706A MY196762A (en) 2016-02-05 2017-02-04 Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms
MX2018009500A MX2018009500A (es) 2016-02-05 2017-02-04 Sal de maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus metodos de preparacion y usos de la sal de maleato y formas cristalinas.
BR112018015881-0A BR112018015881B1 (pt) 2016-02-05 2017-02-04 Sal de maleato de agonista de tlr7, formas cristalinas, c, d e e, seus processos de preparação e seus usos, e composições cristalina e farmacêutica
EA201891770A EA038794B1 (ru) 2016-02-05 2017-02-04 Малеатная соль агониста tlr7, ее кристаллические формы c, d и e, способы получения и применение малеатной соли и кристаллических форм
NZ745231A NZ745231A (en) 2016-02-05 2017-02-04 Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms
ES17747003T ES2834303T3 (es) 2016-02-05 2017-02-04 Sal de maleato de agonista de TLR7, formas cristalinas C, D y E de la misma, métodos de preparación y usos de la sal de maleato y las formas cristalinas
JP2018540750A JP6898336B2 (ja) 2016-02-05 2017-02-04 Ｔｌｒ７アゴニストのマレイン酸塩、その結晶形ｃ、ｄ及びｅ、マレイン酸塩及び結晶形の調製方法及び使用
CN201780009746.0A CN108602830B (zh) 2016-02-05 2017-02-04 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e及其制备方法和用途
CA3013682A CA3013682C (en) 2016-02-05 2017-02-04 Maleate salt of a pyrrolo[3,2-d]pyrimidine compound as tlr7 agonist and crystalline forms c, d and e thereof
AU2017215800A AU2017215800B2 (en) 2016-02-05 2017-02-04 TLR7 agonist maleate salt, crystalline forms C, D and E thereof, preparation methods and uses of maleate salt and crystalline forms
KR1020187024626A KR102393279B1 (ko) 2016-02-05 2017-02-04 Tlr7 작용제 말레에이트 염, 이의 결정형 c, d 및 e, 말레에이트 염 및 결정형의 제조 방법 및 용도
SG11201806682TA SG11201806682TA (en) 2016-02-05 2017-02-04 Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms
US16/075,080 US10780091B2 (en) 2016-02-05 2017-02-04 TLR7 agonist maleate salt, crystalline forms C, D and E thereof, preparation methods and uses of maleate salt and crystalline forms
DK17747003.6T DK3412671T3 (da) 2016-02-05 2017-02-04 TLR7-agonist-maleatsalt, krystallinske former C, D og E deraf, fremgangsmåder til fremstilling og anvendelser af maleatsalt og krystallinske former
EP17747003.6A EP3412671B1 (en) 2016-02-05 2017-02-04 Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms
UAA201809085A UA123781C2 (uk) 2016-02-05 2017-02-04 Малеатна сіль агоніста tlr7, її кристалічні форми c, d і e, способи одержання і застосування малеатної солі і кристалічних форм
ZA2018/05185A ZA201805185B (en) 2016-02-05 2018-08-01 Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms
IL260965A IL260965B (en) 2016-02-05 2018-08-02 The malate salt as an agonist of tlr7, its c, d and e crystal structures, preparation methods and uses of the malate salt and the crystal structures
PH12018501644A PH12018501644A1 (en) 2016-02-05 2018-08-02 Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms
HK19101224.5A HK1259175A1 (zh) 2016-02-05 2019-01-24 一種tlr7激動劑的馬來酸鹽、其晶型c、晶型d、晶型e及其製備方法和用途
US16/991,639 US20200368241A1 (en) 2016-02-05 2020-08-12 Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610082030.0A CN107043380A (zh) 2016-02-05 2016-02-05 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
CN201610082030.0 2016-02-05

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/075,080 A-371-Of-International US10780091B2 (en) 2016-02-05 2017-02-04 TLR7 agonist maleate salt, crystalline forms C, D and E thereof, preparation methods and uses of maleate salt and crystalline forms
US16/991,639 Continuation US20200368241A1 (en) 2016-02-05 2020-08-12 Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms

Publications (1)

Publication Number Publication Date
WO2017133683A1 true WO2017133683A1 (zh) 2017-08-10

Family

ID=59500111

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/072890 WO2017133683A1 (zh) 2016-02-05 2017-02-04 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e及其制备方法和用途

Country Status (24)

Country Link
US (2) US10780091B2 (zh)
EP (1) EP3412671B1 (zh)
JP (1) JP6898336B2 (zh)
KR (1) KR102393279B1 (zh)
CN (2) CN107043380A (zh)
AR (1) AR107547A1 (zh)
AU (1) AU2017215800B2 (zh)
CA (1) CA3013682C (zh)
CL (1) CL2018002089A1 (zh)
DK (1) DK3412671T3 (zh)
EA (1) EA038794B1 (zh)
ES (1) ES2834303T3 (zh)
HK (1) HK1259175A1 (zh)
HU (1) HUE052211T2 (zh)
IL (1) IL260965B (zh)
MX (1) MX2018009500A (zh)
MY (1) MY196762A (zh)
NZ (1) NZ745231A (zh)
PH (1) PH12018501644A1 (zh)
SG (1) SG11201806682TA (zh)
TW (1) TWI778951B (zh)
UA (1) UA123781C2 (zh)
WO (1) WO2017133683A1 (zh)
ZA (1) ZA201805185B (zh)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020162705A1 (ko) 2019-02-08 2020-08-13 성균관대학교산학협력단 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도
WO2021177679A1 (ko) 2020-03-02 2021-09-10 성균관대학교산학협력단 병원균 외벽 성분 기반 생병원체 모방 나노 입자 및 그 제조 방법
WO2022031057A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 활성화 부위가 일시적으로 비활성화된 톨-유사 수용체 7 또는 8 작용자와 기능성 약물의 결합체 및 그 용도
WO2022031021A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적 제어가 가능한 아주번트를 포함하는 mrna 백신
WO2022031011A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적으로 작용하는 아주번트 앙상블

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107043380A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
CN107043378A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体
CN107043379A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的晶型a、其制备方法和医药用途
US20210220362A1 (en) * 2018-05-25 2021-07-22 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tlr7 agonist and pharmaceutical combination thereof for treating lung cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104780923A (zh) * 2012-11-20 2015-07-15 葛兰素史克有限责任公司 新颖的化合物
CN104780924A (zh) * 2012-11-20 2015-07-15 葛兰素史克有限责任公司 新颖的化合物
CN104837840A (zh) * 2012-10-10 2015-08-12 爱尔兰詹森科学公司 用于治疗病毒感染及其他疾病的吡咯并[3,2-d]嘧啶衍生物
WO2015168269A1 (en) * 2014-05-01 2015-11-05 Novartis Ag Compounds and compositions as toll-like receptor 7 agonists
WO2016023511A1 (zh) * 2014-08-15 2016-02-18 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3376479B2 (ja) * 1991-08-12 2003-02-10 武田薬品工業株式会社 縮合ピリミジン誘導体、その製造法および用途
TW552261B (en) 1996-07-03 2003-09-11 Japan Energy Corp Novel purine derivative
AU732361B2 (en) 1997-11-28 2001-04-26 Dainippon Sumitomo Pharma Co., Ltd. Novel heterocyclic compounds
WO2007024707A2 (en) 2005-08-22 2007-03-01 The Regents Of The University Of California Tlr agonists
US7968544B2 (en) 2007-06-29 2011-06-28 Gilead Sciences, Inc. Modulators of toll-like receptor 7
CA2707030A1 (en) 2007-08-03 2009-02-12 Pfizer Limited Imidazopyridinones
WO2010077613A1 (en) 2008-12-09 2010-07-08 Gilead Sciences, Inc. Modulators of toll-like receptors
US9139590B2 (en) 2011-02-04 2015-09-22 Duquesne University Of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
EP2800569B1 (en) * 2012-01-05 2018-07-25 Northeastern University Allosteric modulators of cb1 cannabinoid receptors
EP2922549B1 (en) 2012-11-20 2017-06-21 Glaxosmithkline LLC Novel compounds
RU2676684C2 (ru) 2014-02-20 2019-01-10 ГлаксоСмитКлайн Интеллекчуал Проперти (No.2) Лимитед ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНДУКТОРОВ ЧЕЛОВЕЧЕСКОГО ИНТЕРФЕРОНА
EA032487B1 (ru) * 2014-05-01 2019-06-28 Новартис Аг Соединения и композиции в качестве агонистов toll-подобного рецептора 7
CN105367576A (zh) * 2014-08-15 2016-03-02 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
CN105732635A (zh) 2014-12-29 2016-07-06 南京明德新药研发股份有限公司 一类Toll样受体7激动剂
US10676478B2 (en) 2015-11-05 2020-06-09 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 7-(thiazol-5-yl) pyrrolopyrimidine compound as TLR7 agonist
TWI714661B (zh) 2015-11-05 2021-01-01 法商賽諾菲公司 新穎念珠藻素化合物及接合物、其製備與其治療用途
CA3002299A1 (en) 2015-11-05 2017-05-11 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
CN107043379A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的晶型a、其制备方法和医药用途
CN107043380A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
CN107043377A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途
CN107043378A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104837840A (zh) * 2012-10-10 2015-08-12 爱尔兰詹森科学公司 用于治疗病毒感染及其他疾病的吡咯并[3,2-d]嘧啶衍生物
CN104780923A (zh) * 2012-11-20 2015-07-15 葛兰素史克有限责任公司 新颖的化合物
CN104780924A (zh) * 2012-11-20 2015-07-15 葛兰素史克有限责任公司 新颖的化合物
WO2015168269A1 (en) * 2014-05-01 2015-11-05 Novartis Ag Compounds and compositions as toll-like receptor 7 agonists
WO2016023511A1 (zh) * 2014-08-15 2016-02-18 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020162705A1 (ko) 2019-02-08 2020-08-13 성균관대학교산학협력단 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도
WO2021177679A1 (ko) 2020-03-02 2021-09-10 성균관대학교산학협력단 병원균 외벽 성분 기반 생병원체 모방 나노 입자 및 그 제조 방법
WO2022031057A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 활성화 부위가 일시적으로 비활성화된 톨-유사 수용체 7 또는 8 작용자와 기능성 약물의 결합체 및 그 용도
WO2022031021A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적 제어가 가능한 아주번트를 포함하는 mrna 백신
WO2022031011A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적으로 작용하는 아주번트 앙상블

Also Published As

Publication number Publication date
IL260965B (en) 2022-02-01
JP6898336B2 (ja) 2021-07-07
AU2017215800A1 (en) 2018-08-30
US20190070179A1 (en) 2019-03-07
DK3412671T3 (da) 2020-11-09
US20200368241A1 (en) 2020-11-26
ZA201805185B (en) 2024-08-28
ES2834303T3 (es) 2021-06-17
EA201891770A1 (ru) 2019-01-31
CN108602830A (zh) 2018-09-28
CN108602830B (zh) 2020-07-28
JP2019505532A (ja) 2019-02-28
EP3412671A1 (en) 2018-12-12
NZ745231A (en) 2022-07-29
EP3412671B1 (en) 2020-09-16
TW201728588A (zh) 2017-08-16
UA123781C2 (uk) 2021-06-02
EP3412671A4 (en) 2019-07-24
KR102393279B1 (ko) 2022-05-02
KR20180104116A (ko) 2018-09-19
MX2018009500A (es) 2018-12-11
US10780091B2 (en) 2020-09-22
HK1259175A1 (zh) 2019-11-29
HUE052211T2 (hu) 2021-04-28
BR112018015881A2 (pt) 2018-12-26
SG11201806682TA (en) 2018-09-27
TWI778951B (zh) 2022-10-01
MY196762A (en) 2023-05-03
CN107043380A (zh) 2017-08-15
AR107547A1 (es) 2018-05-09
PH12018501644A1 (en) 2019-06-03
CA3013682C (en) 2022-06-21
AU2017215800B2 (en) 2020-08-20
CL2018002089A1 (es) 2018-12-07
EA038794B1 (ru) 2021-10-20
CA3013682A1 (en) 2017-08-10

Similar Documents

Publication Publication Date Title
WO2017133684A1 (zh) 一种tlr7激动剂的晶型a、其制备方法和用途
WO2017133683A1 (zh) 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e及其制备方法和用途
WO2017133687A1 (zh) 一种tlr7激动剂的三氟乙酸盐、晶型b、制备方法和用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17747003

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 260965

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2018540750

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2018/009500

Country of ref document: MX

Ref document number: 3013682

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 11201806682T

Country of ref document: SG

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018015881

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20187024626

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017215800

Country of ref document: AU

Date of ref document: 20170204

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201809085

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: 201891770

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2017747003

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2017747003

Country of ref document: EP

Effective date: 20180905

ENP Entry into the national phase

Ref document number: 112018015881

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20180803